EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS.

EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive paralysis due to motor neuron death. Several lines of published evidence suggested that inhibition of epidermal growth factor receptor (EGFR) signaling might protect neurons from degeneration. To test th...

Full description

Bibliographic Details
Main Authors: Claire E Le Pichon, Sara L Dominguez, Hilda Solanoy, Hai Ngu, Nicholas Lewin-Koh, Mark Chen, Jeffrey Eastham-Anderson, Ryan Watts, Kimberly Scearce-Levie
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3637182?pdf=render

Internet

http://europepmc.org/articles/PMC3637182?pdf=render

Similar Items